Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bronchodilator · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Bronchodilator | DRUG | - |
Inclusion Criteria: * Persistent asthma for a minimum of six months duration that has been stable for at least four weeks * Predicted FEV1 60-90% * Demonstration of 12% airway reversibility Exclusion Criteria: * Continuous requirement for beta-blockers, monoamine oxidase (MAO) inhibitors, tricycl...
Bronchodilator is an investigational small molecule being developed for the treatment of asthma. It is currently in Phase 2 clinical development and is being studied in pediatric patients with asthma.
Bronchodilator is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker TEVA. The drug is currently in Phase 2 clinical trials for asthma.
Bronchodilator is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial for the drug has been completed.
Bronchodilator has one completed Phase 2 clinical trial with the identifier NCT00112411, titled 'Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics'. The trial was conducted in the United States and enrolled pediatric patients aged 4 years and older with asthma.
Bronchodilator is the name used for the drug in clinical development. No alternative names have been established for this investigational product.